foxo4-dri senolytic peptide human trials The disordered p53 transactivation domain is the target of FOXO4 and the compound Molecular modelling of the FOXO4-TP53

foxo4-dri senolytic peptide human trials

foxo4-dri senolytic peptide human trials The disordered p53 transactivation domain is the target of FOXO4 and the compound Molecular modelling of the FOXO4-TP53

Name: foxo4-dri senolytic peptide human trials The disordered p53 transactivation domain is the target of FOXO4 and the compound Molecular modelling of the FOXO4-TP53
Brand: haus-pacher.at
SKU: 16895418320
Price: 25.21 USD
Availability: InStock
Rating: 4.7029000000000005 (21 reviews)

SKU: 16895418320

4.7

USD25.21 USD67.21

Pay in 4 interest-free payments of $6.30 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

Peptide Therapies (BPC-157) BPC-157 is a synthetic peptide marketed online as an injury-healing solution

Our Clinic Director will inform you at the time of your appointment and guide you through the process

Research Applications

PMID 28988575

Research Focus: Ideal for studies involving metabolic pathways, glucose regulation, and appetite control

5-Amino-1MQ (5-Amino-1-Methylquinolinium) as distributed by Peptides Lab UK is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment